Table 1. Main Characteristics of included trials.
| Trial | Year of publication | Period of enrollment | Multi-centre | Patients number | Mean age (years) | Male (%) | ACS type | Rescue PCI (%) | Follow-up | Gp IIb/IIIa inhibitors (%) | Type of Gp IIb/IIIa inhibitors | Hemostasis | Crossover (%) | |||||||
| TFA | TRA | TFA | TRA | TFA | TRA | TFA | TRA | TFA | TRA | TFA | TRA | TFA | TRA | |||||||
| FARMI (16) | 2007 | 2004-05 | No | 57 | 57 | 60 | 58 | 86 | 82.5 | STEMI | 49.1 | 35.1 | In-hospital | 100 | 100 | Abciximab | manual compression | manual compression | 1.8 | 12.3 |
| Gan et al. (17) | 2009 | 2004-07 | Yes | 105 | 90 | 52.3 | 53.6 | 80 | 81.1 | STEMI | 0 | 0 | In-hospital | 34.3 | 31.1 | N.A. | manual compression | manual compression | 0 | 1.1 |
| Hou et al. (18) | 2010 | 2005-08 | No | 100 | 100 | 66.2 | 64.9 | 69 | 72 | STEMI | 0* | 0* | 30-day | 20 | 28 | Tirofiban | manual compression | TR-Band | 0 | 4 |
| Mann et al. (19) | 1998 | 1997 | No | 77 | 65 | 62 | 63 | 78 | 65 | STEMINSTEMIUA | N.A. | N.A. | In-hospital | 10 | 15 | Abciximab | manual compression + FemoStop | radial artery compression device | 0 | 13.8 |
| RADIAL-AMI (20) | 2005 | N.A. | Yes | 25 | 25 | 58 | 52 | 0 | 76 | STEMI | 68 | 64 | 30-day | 92 | 95 | Abciximab Tirofiban Eptifibatide | manual compression (92%). VCD (8%). | manual compression | 0 | 4 |
| RADIAMI (21) | 2009 | 2005-06 | No | 50 | 50 | 59.1 | 59.9 | 48.5 | 51.5 | STEMI | 0 | 0 | In-hospital | 42 | 44 | Abciximab | manual compression | TR-Band | 2 | 8 |
| RADIAMI II (22) | 2011 | 2006-08 | No | 59 | 49 | 57.6 | 62.1 | 63 | 65 | STEMI | 0* | 0* | In-hospital | 54 | 51 | Abciximab | StarClose device | TR-Band | 1.7 | 4.1 |
| RIFLE-STEACS (23) | 2012 | 2009-11 | Yes | 501 | 500 | 65 | 65 | 71.9 | 74.8 | STEMI | 7 | 8.2 | 30-day | 69.9 | 67.4 | N.A. | N.A. | N.A. | 2.8 | 9.6 |
| RIVAL (24) | 2011 | 2006-10 | Yes | 3,514 | 3,507 | 62 | 62 | 72.9 | 74.1 | STEMINSTEMIUA | 11.1 | 10.6 | 30-day | 24 | 25.3 | N.A. | manual compression (74.4%). VCD (25.6%) | N.A. | 0.9 | 7 |
| TEMPURA (25) | 2003 | 1999-2001 | No | 72 | 77 | 67 | 66 | 81.9 | 80.5 | STEMI | 0* | 0* | In-hospital | 0† | 0† | - | manual compression | manual compression | 0 | 1.5 |
| Wang et al. (26) | 2012 | 2008-10 | No | 59 | 60 | 60.2 | 59.8 | 83.1 | 86.7 | STEMI‡ | N.A. | N.A. | In-hospital | 50.8 | 55 | Tirofiban | manual compression | manual compression | 1.7 | 6.7 |
* Only patients treated with primary PCI were enrolled.
†
Glycoprotein IIb/IIIa inhibitors were not given in any of the patients because not approved for clinical use in Japan.
‡
STEMI patients receiving routine early PCI within 12 hours after thrombolysis were enrolled.
PCI, Percutaneous coronary intervention; ACS, Acute coronary syndrome; STEMI, ST-segment elevation myocardial infarction; NSTEMI, Non-ST-segment elevation myocardial infarction; UA, Unstable angina; TFA, Transfemoral approach; TRA, Transradial approach; VCD, vascular closure devices; N.A., Not available data.